CB2 cannabinoid receptor effects on the blood-brain barrier in HIV depended on receptor levels

Both endothelial cell lines responded similarly to HIV-conditioned media (increased permeability, decreased tight junction proteins). However, CB2 receptor activation improved all barrier measures in hCMEC/D3 cells (high CB2 expression, 50-fold higher cAMP response) while showing no benefit or aggravation in HBMEC/ci18 cells (low CB2 expression).

Researchers used two human brain endothelial cell lines (hCMEC/D3 and HBMEC/ci18) in multicellular blood-brain barrier models. Cells were exposed to conditioned media from HIV latently infected promonocytes and treated with cannabinoid receptor agonists. Barrier integrity was assessed via dextran permeability, tight junction proteins, cell viability, proliferation, and GPCR-mediated cAMP production.

Cannabis use is common among people living with HIV, and blood-brain barrier disruption contributes to HIV-associated neurocognitive disorders. This study shows that whether cannabinoids help or harm the barrier may depend on individual differences in CB2 receptor expression, potentially explaining conflicting findings in previous research.

This finding has important implications: if CB2 receptor density varies between individuals, cannabis could protect the blood-brain barrier in some people living with HIV while worsening it in others. This context-dependent effect aligns with previous clinical observations of variable cannabis outcomes in HIV populations.

In vitro cell line models do not fully replicate the complexity of the human blood-brain barrier. Only two cell lines were compared. HIV exposure was via conditioned media rather than direct infection. Individual variation in CB2 expression in living humans is not well characterized.